Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Basic characteristics of the study population

From: Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study

Variable Gout   Non-gout
Number Percentage Number Percentage
Total number 41,446   41,446  
Mean age (SD) 57.2 (13.6) 57.1 (13.7)
Median follow up (IQR) 6.0 (3.3, 9.5) 5.9 (3.2, 9.4)
Male 33,574 81.0 33,574 81.0
Body mass index
 Normal 7394 17.8 12,341 29.8
 Underweight 349 0.8 681 1.6
 Overweight 15,537 37.5 14,760 35.6
 Obese 15,311 36.9 8417 20.3
 Missing 2855 6.9 5247 12.7
Smoking status
 Never/ex-smoker 36,153 87.2 34,406 83.0
 Current smoker 5293 12.8 7040 17.0
Comorbidities
 Diabetes mellitus 2686 6.5 2417 5.8
 Treated hypertension 11,982 28.9 6648 16.0
 Rheumatoid arthritis 276 0.7 302 0.7
 SLE 25 0.1 24 0.1
 Heart failure 1342 3.2 482 1.2
 Myocardial infarction 1660 4.0 1166 2.8
 Cerebrovascular disease 1537 3.7 1241 3.0
 Peripheral vascular disease 901 2.2 670 1.6
 Anti-diabetic drugs 1847 4.5 1881 4.5
 NSAIDs 5852 14.1 1619 3.9
 Previous hospitalisations 11,016 26.6 9129 22.0
GP consultation rates (tertiles)
 1 10,375 25.0 17,256 41.6
 2 14,609 35.2 13,022 31.4
 3 16,462 39.7 11,168 26.9
IMD quintiles
 1 (least deprived) 10,526 25.4 10,485 25.3
 2 10,220 24.7 10,232 24.7
 3 8411 20.3 8330 20.1
 4 7034 17.0 7164 17.3
 5 (most deprived) 5216 12.6 5206 12.6
  1. SLE systemic lupus erythematosus, NSAID non-steroidal anti-inflammatory drug, GP general practitioner, IMD Index of multiple deprivation